How Much Does Edarbi Cost?

Our most recent US pharmacy data shows a low of roughly $104.61 for Azilsartan Medoxomil with a standard discount card. That figure moves with dosage and quantity — check the comparison table for the exact combination you need.

We found Canadian pricing for Azilsartan Medoxomil starting near $0.670 per tablet in USD terms. That's before any shipping charge, which the table above breaks out separately.

Drug pricing is set separately in each country through different negotiation, regulatory, and distribution systems, so the same medication can legitimately carry different price tags on either side of the border. Check the comparison table above for the specific numbers on Azilsartan Medoxomil.

Generic and brand-name pricing for Azilsartan Medoxomil is broken out in the tables above where both exist in our data. Generic versions are typically the lower-cost option, but availability depends on the specific formulation and dosage.

Your out-of-pocket cost for Edarbi with insurance depends on your specific plan's formulary (list of covered drugs), deductible, and copay or coinsurance structure. It's best to check with your pharmacist or insurer for your exact price. For some patients, especially those with high deductibles or plans that don't cover the medication favorably, a pharmacy savings card might offer a lower price than the insurance copay. Comparing prices at different pharmacies using such a program can help identify the most affordable option.

Coverage for Edarbi under Medicare Part D prescription drug plans is not guaranteed and varies by plan. If it is not covered on your plan's formulary, you would typically be responsible for the full retail price. In such cases, using a pharmacy discount program could provide an alternative way to obtain savings, potentially lowering the cost to a fixed, reduced price per fill. It's advisable to review your plan's coverage details each year.

No, a generic equivalent for Edarbi (azilsartan medoxomil) is not currently available in the United States. It remains a brand-name medication marketed by Takeda Pharmaceutical Company and Arbor Pharmaceuticals.